Head-To-Head Survey: AIT Therapeutics (AITB) & Alliqua Biomedical (ALQA)
AIT Therapeutics (OTCMKTS:AITB) and Alliqua Biomedical (NASDAQ:ALQA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, risk, earnings and profitability.
Risk & Volatility
AIT Therapeutics has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500. Comparatively, Alliqua Biomedical has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500.
This is a summary of current ratings and recommmendations for AIT Therapeutics and Alliqua Biomedical, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
AIT Therapeutics presently has a consensus target price of $16.00, indicating a potential upside of 384.85%. Alliqua Biomedical has a consensus target price of $2.80, indicating a potential upside of 67.16%. Given AIT Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe AIT Therapeutics is more favorable than Alliqua Biomedical.
Earnings & Valuation
This table compares AIT Therapeutics and Alliqua Biomedical’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|AIT Therapeutics||N/A||N/A||-$18.04 million||($3.01)||-1.10|
|Alliqua Biomedical||$19.57 million||0.43||-$25.70 million||($6.49)||-0.26|
AIT Therapeutics has higher earnings, but lower revenue than Alliqua Biomedical. AIT Therapeutics is trading at a lower price-to-earnings ratio than Alliqua Biomedical, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
21.8% of Alliqua Biomedical shares are owned by institutional investors. 13.2% of Alliqua Biomedical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares AIT Therapeutics and Alliqua Biomedical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
AIT Therapeutics beats Alliqua Biomedical on 8 of the 13 factors compared between the two stocks.
About AIT Therapeutics
AIT Therapeutics, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria. The company was founded in 2011 and is based in Harrison, New York.
About Alliqua Biomedical
Alliqua BioMedical, Inc., a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company markets MIST Ultrasound Healing Therapy, a painless noncontact low-frequency ultrasound to promote healing; and Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix, which are human biologic regenerative technologies. It also provides contract manufacturing services, including the development, manufacture, and marketing of high water content, electron beam cross-linked, and aqueous polymer hydrogels or gels used in wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company is headquartered in Yardley, Pennsylvania.
Receive News & Ratings for AIT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.